Download curriculum vitae

CURRICULUM VITAE
Nome: Luigi Varesio
Data e Luogo di nascita: 6 Luglio 1951; Torino, Italia
Cittadinanza: USA, Italiana
Stato civile: Sposato; due figli
Posizione Attuale: Direttore del Laboratorio di Biologia Molecolare, Istituto Giannina
Gaslini
Titoli di Studio:
1970 - Maturità Scientifica Liceo "G.Ferraris", Torino
1974 - Laurea in Scienze Biologiche (con lode) presso l’Università' di Torino
1977 - Specializzazione in Microbiologia presso l' Università di Torino
2014 Corso di formazione manageriale per Dirigenti di Struttura Complessa presso Cisef,
Genova
Breve elenco degli impieghi:
1969-1970 - Studente interno presso i Laboratori del Liceo Scientifico “G. Ferraris” di Torino
1970-1974 - Studente interno presso l’Istituto di Microbiologia dell'Universita' di Torino.
1974-1977 - Borsa di studio Postdottorato presso il Dipartimento di Microbiologia, Scuola di
Medicina, Universita' di Torino.
1977-1980 - Visiting Fellow, Laboratory Immunodiagnosis National Cancer Institute,
Bethesda, MD, USA
1980-1981 - Visiting Associate, Laboratory Immunodiagnosis National Cancer Institute,
Bethesda, MD, USA
1981-1983 - Visiting Associate, Biological Response Modifiers Program, National Cancer
Institute, Frederick, MD, USA
1983-1993 - Visiting Scientist, Laboratory Molecular Immunoregulation, Biological
Response Modifiers Program, National Cancer Institute, Frederick, MD, USA
1983-1985 - Direttore, Sezione di Immunobiologia, Laboratory of Molecular
Immunoregulation, National Cancer Institute, Frederick, MD, USA
1985-1993 - Direttore, Sezione di Immunobiologia, Laboratory Experimental Immunology,
National Cancer Institute, Frederick,
MD, USA
1993-1996- Direttore, sezione Macrophage Cell Biology, Laboratory Experimental
Immunology, National Cancer Institute, Frederick, MD, USA
1995-1998 - Direttore, Servizio di Genetica Molecolare, Istituto “G. Gaslini”, Genova, Italia
1994-oggi - Direttore, Servizio di Biologia Molecolare, Istituto “G. Gaslini”, Genova, Italia
1999-oggi - Professore, Biologia Molecolare, Scuola di Specializzazione in Malattie Infettive,
Facoltà di Medicina, Università di Genova, Genova, Italia
1999-oggi - Professore di Biologia Molecolare presso la Scuola di Specializzazione in
Genetica Medica, Facoltà di Medicina, Genova, Italia
1
Pubblicazioni ultimi 5 anni:
1. Varesio L, Battaglia F, Raggi F, Ledda B, Bosco MC. Macrophage-inflammatory
protein-3alpha/CCL-20 is transcriptionally induced by the iron chelator desferrioxamine
in human mononuclear phagocytes through nuclear factor (NF)-kappaB. Mol Immunol
2010;47:685-693.
2. Fardin P, Barla A, Mosci S et al. A biology-driven approach identifies the hypoxia gene
signature as a predictor of the outcome of neuroblastoma patients. Mol Cancer
2010;9:185.
3. Fardin P, Cornero A, Barla A et al. Identification of multiple hypoxia signatures in
neuroblastoma cell lines by l1-l2 regularization and data reduction. J
Biomed.Biotechnol. 2010;2010:878709.
4. Bosco MC, Varesio L. Monocytic cell gene regulation by the hypoxic synovial
environment in juvenile idiopathic arthritis: implications for disease pathogenesis.
Journal of Clinical Rheumatology & Musculoskeletal Medicine 2010;1:1-9.
5. Bosco MC, Pierobon D, Blengio F et al. Hypoxia modulates the gene expression profile
of immunoregulatory receptors in human mature dendritic cells: identification of
TREM-1 as a novel hypoxic marker in vitro and in vivo. Blood 2011;117:2625-2639.
6. Sica A, Melillo G, Varesio L. Hypoxia: a double-edged sword of immunity. J Mol Med
2011;89:657-665.
7. Ognibene M, Barbieri O, Vanni C et al. High frequency of development of B cell
lymphoproliferation and diffuse large B cell lymphoma in Dbl knock-in mice. J Mol
Med 2011;89:493-504.
8. Resaz R, Emionite L, Vanni C et al. Treatment of newborn G6pc(-/-) mice with bone
marrow-derived myelomonocytes induces liver repair. J Hepatol. 2011;55:1263-1271.
9. Ognibene M, Vanni C, Segalerba D et al. The tumor suppressor hamartin enhances Dbl
transforming activity through interaction with ezrin. J Biol Chem. 2011;89:493-504.
10. Blengio F, Raggi F, Pierobon D et al. The hypoxic environment reprograms the
cytokine/chemokine expression profile of human mature dendritic cells. Immunobiology
2013;218:76-89.
11. Cornero A, Acquaviva M, Fardin P et al. Design of a multi-signature ensemble classifier
predicting neuroblastoma patients' outcome. BMC Bioinformatics 2012;13 Suppl 4:S13.
12. Petecchia L, Sabatini F, Usai C et al. Cytokines induce tight junction disassembly in
airway cells via an EGFR-dependent MAPK/ERK1/2-pathway. Lab Invest
2012;92:1140-1148.
2
13. Bosco MC, Varesio L. Dendritic cell reprogramming by the hypoxic environment.
Immunobiology 2012;217:1241-1249.
14. Cattelani S, Ferrari-Amorotti G, Galavotti S et al. The p53 codon 72 Pro/Pro genotype
identifies poor-prognosis neuroblastoma patients: correlation with reduced apoptosis and
enhanced senescence by the p53-72P isoform. Neoplasia. 2012;14:634-643.
15. Molenaar JJ, Domingo-Fernandez R, Ebus ME et al. LIN28B induces neuroblastoma
and enhances MYCN levels via let-7 suppression. Nat Genet. 2012;44:1199-1206.
16. Pierobon D, Bosco MC, Blengio F et al. Chronic hypoxia reprograms human immature
dendritic cells by inducing a proinflammatory phenotype and TREM-1 expression. Eur.J
Immunol 2013;43:949-966.
17. Cangelosi D, Blengio F, Versteeg R et al. Logic Learning Machine creates explicit and
stable rules stratifying neuroblastoma patients. BMC Bioinformatics 2013;14:S12.
18. Amendola R, Cervelli M, Tempera G et al. Spermine metabolism and radiation-derived
reactive oxygen species for future therapeutic implications in cancer: an additive or
adaptive response. Amino.Acids 2013;13:1579-1599.
19. Bosco MC, Varesio L. Hypoxia and Gene Expression. In: Melillo G, ed. Hypoxia and
cancer.: Humana Press; 2013:91-119.
20. Balsamo M, Manzini C, Pietra G et al. Hypoxia downregulates the expression of
activating receptors involved in NK-cell-mediated target cell killing without affecting
ADCC. Eur.J.Immunol. 2013;43:2756-2764.
21. Ognibene M, Vanni C, Blengio F et al. Identification of a novel mouse Dbl protooncogene splice variant: Evidence that SEC14 domain is involved in GEF activity
regulation. Gene 2014;537:220-229.
3